In a new article, the International Agency for Research on Cancer (IARC) and partners compare the protection offered against incident and persistent human papillomavirus (HPV) infections in women receiving two or three doses of quadrivalent vaccine at 15-18 years of age. The results, published in Papillomavirus Research, are based on an ongoing multi-centric study in India.
Based on the analysis of nearly 1500 women, researchers reported significant protection against incident as well as persistent infections of vaccine-targeted HPV types offered by two doses of quadrivalent vaccine in girls at 15-18 years of age. These new results make a strong argument to extend the current World Health Organization two-dose recommendation to 15-18 year old girls.
Basu P, Muwonge R, Bhatla N, Nene BM, Joshi S, Esmy PO, et al.
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study
Papillomavirus Res, Published online 31 January 2019;